The phase 3 OAK trial, which compared atezolizumab with docetaxel in NSCLC, the CRP flare was predictive of improved survival only in the immunotherapy arm, supporting its potential as a tumor-agnostic, immunotherapy-specific marker (139). Here, CRP is linked to neoplasm.